Humanetics’ BIO 300 Shows Promise in Preventing Radiation-induced ED and Tumor Growth in Prostate Cancer

Humanetics’ BIO 300 Shows Promise in Preventing Radiation-induced ED and Tumor Growth in Prostate Cancer
A recent study using animals demonstrated that Humanetics' BIO 300 reduces radiation-induced erectile dysfunction and slows tumor growth. Radiation-induced erectile dysfunction is a common side effect observed in more than half of men treated with radiation therapy for prostate cancer. There currently are no FDA-approved drugs to mitigate radiation-induced erectile dysfunction. BIO 300 (nano-genistein) has been developed by Humanetics Corporation to reduce radiation-associated toxicities in multiple cancers. It already is being studied in Phase 1b/2a clinical trials in patients with non-small cell lung cancer receiving chemoradiotherapy. The drug now is being evaluated by Humanetics for preventing radiation-induced erectile dysfunction. Data recently presented during the annual meetings of the American Society for Radiation Oncology (ASTRO) and the Radiation Research Society (RRS) has shown that the drug, given before or after radiation, significantly improved erectile dysfunction in animal models. The study, "Treatment With Nano-Genistein for the Prevention of Radiation-Induced Erectile Dysfunction," involved testing the drug in a rat model. Animal prostates were irradiated and treated with nano-genistein three days prior to irradiation for 14 weeks. A bioassay to assess erectile dysfunction was carried out at four, nine, and 14 weeks following irradiation
Subscribe or to access all post and page content.